Under Major Complications, toward the bottom of the page.
Explains that patients with cirrhosis experience a decrease in production of clotting factors and diminished clearance of anticoagulants. Portal hypertension may result in hypersplenism which is associated with thrombocytopenia. Also, diminished vitamin K absorption (as in patients with chronic cholestatic syndrome or decreased hepatic mass) can interfere with production of some of the vitamin k-dependent clotting factors.
Regarding hypercoagulability, most studies seem to address portal vein thrombosis rather than a risk for any thrombosis.
This review identifies three case-control studies that look at the risk of VTE in hospitalized patients: 1) 625 cases with VTE & severe liver disease v. 625 controls – reduced risk of VTE in patients with severe liver disease; 2) 6500 cases VTE v. 10,000 controls – non-significant risk of VTE (RR 1.65) in patients with chronic liver disease. The third study aimed to assess risk of VTE in patients with cirrhosis; 963 patients with cirrhosis v. 12,405 hospitalized patients without cirrhosis. Incidence of DVT/PE in cases was 1.8% v. 0.9% in controls. In multivariate analysis, the presence of cirrhosis was not associated with an increased risk in DVT/PE (OR, 0.87). The article does discuss mechanisms for hypercoagulability that has been observed in plasma taken from cirrhotic patients.